ADVENTRX announces Exelbine 12-month stability test results

NewsGuard 100/100 Score
Sep 15 2010

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site.  

The 12-month stability data are consistent with the stability data collected at 6 and 9 months and will support the Company's submission of a New Drug Application (NDA) for Exelbine, which the Company expects to take place in the fourth quarter of this year.

Source:

ADVENTRX Pharmaceuticals, Inc.

Posted in: Drug Trial News

Tags: , , , ,

Comments (0)

Suggested Reading

Recycled food waste may be contaminated with pharmaceutical residues, research reveals
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
LabVantage celebrates customer success with record number of software deployments in FY 2024
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Lancet Commission predicts sharp increase in global prostate cancer cases
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study highlights global fertility decline and its implications for the future